![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhlAqiXlWUd9bZHipeDo8cpA1TWzpvQBKL9nBYNkrDNLj4S9Igh2sKB_NhS7bZGbfLAS2VqGLKVCs3MwCoYCwF4z3w0Km6oHtwkUul8kcBKi5duJrdNF8Ceb05WBHGwr3EiIJwhMr2Ca3Up/s320/ngc_email_hdr.gif)
GUIDELINE TITLE
Secondary prevention of coronary artery disease.
BIBLIOGRAPHIC SOURCE(S)
University of Michigan Health System. Secondary prevention of coronary artery disease. Ann Arbor (MI): University of Michigan Health System; 2009 Mar. 11 p.
GUIDELINE STATUS
This is the current release of the guideline.
** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.
July 1, 2009 - Chantix or Champix (Varenicline) and Zyban or Wellbutrin (bupropion or amfebutamone): The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products. These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide.
abrir aquí para acceder al documento AHRQ NGC completo:
Secondary prevention of coronary artery disease.
No hay comentarios:
Publicar un comentario